Subjective health expectations of patients with age-related macular degeneration treated with antiVEGF drugs
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2318
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Subjective health expectations of patients with age-related macular degeneration treated with antiVEGF drugs ; volume:17 ; number:1 ; day:10 ; month:10 ; year:2017 ; pages:1-9 ; date:12.2017
BMC geriatrics ; 17, Heft 1 (10.10.2017), 1-9, 12.2017
- Keyword
-
Augenheilkunde
Augenkrankheit
- Creator
-
Péntek, Márta
- Contributor
-
Brodszky, Valentin
Biró, Zsolt
Kölkedi, Zsófia
Dunai, Árpád
Németh, János
Baji, Petra
Rencz, Fanni
Gulácsi, László
Resch, Miklós D.
SpringerLink (Online service)
- DOI
-
10.1186/s12877-017-0619-9
- URN
-
urn:nbn:de:1111-2018011211235
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:51 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Péntek, Márta
- Brodszky, Valentin
- Biró, Zsolt
- Kölkedi, Zsófia
- Dunai, Árpád
- Németh, János
- Baji, Petra
- Rencz, Fanni
- Gulácsi, László
- Resch, Miklós D.
- SpringerLink (Online service)
Other Objects (12)
Development of Macular Atrophy in Patients with Wet Age-Related Macular Degeneration Receiving Anti-VEGF Treatment
Retinal layers changes in patients with age-related macular degeneration treated with intravitreal anti-VEGF agents
Fibrosis in age-related neovascular macular degeneration in the anti-VEGF era
Refractory neovascular age-related macular degeneration: time-dependent changes of central retinal thickness with anti-VEGF treatment
The effect of vitreomacular interface in neovascular age-related macular degeneration treated with intravitreal injection of anti-VEGF
Risk factors for breakthrough vitreous hemorrhage after intravitreal anti-VEGF injection in age-related macular degeneration with submacular hemorrhage
Anti-VEGF for the management of diabetic macular edema
Pachychoroid Neovasculopathy Disguising as Age-Related Macular Degeneration Treated by Spironolactone and Anti-VEGF Combination Therapy
Hyperreflective material evolution patterns during long term anti-VEGF therapy in neovascular age-related macular degeneration
A Systematic Review of the Treat and Extend Treatment Regimen with Anti-VEGF Agents for Neovascular Age-Related Macular Degeneration
Atrophy of retinal vessels in neovascular age-related macular degeneration following long-term treatment with 20 intravitreal anti-VEGF injections
Long term results of patients with neovascular age-related macular degeneration switched from other anti-VEGF agents to intravitreal Aflibercept
Development of Macular Atrophy in Patients with Wet Age-Related Macular Degeneration Receiving Anti-VEGF Treatment
Retinal layers changes in patients with age-related macular degeneration treated with intravitreal anti-VEGF agents
Fibrosis in age-related neovascular macular degeneration in the anti-VEGF era
Refractory neovascular age-related macular degeneration: time-dependent changes of central retinal thickness with anti-VEGF treatment
The effect of vitreomacular interface in neovascular age-related macular degeneration treated with intravitreal injection of anti-VEGF
Risk factors for breakthrough vitreous hemorrhage after intravitreal anti-VEGF injection in age-related macular degeneration with submacular hemorrhage
Anti-VEGF for the management of diabetic macular edema
Pachychoroid Neovasculopathy Disguising as Age-Related Macular Degeneration Treated by Spironolactone and Anti-VEGF Combination Therapy
Hyperreflective material evolution patterns during long term anti-VEGF therapy in neovascular age-related macular degeneration
A Systematic Review of the Treat and Extend Treatment Regimen with Anti-VEGF Agents for Neovascular Age-Related Macular Degeneration
Atrophy of retinal vessels in neovascular age-related macular degeneration following long-term treatment with 20 intravitreal anti-VEGF injections
Long term results of patients with neovascular age-related macular degeneration switched from other anti-VEGF agents to intravitreal Aflibercept
Development of Macular Atrophy in Patients with Wet Age-Related Macular Degeneration Receiving Anti-VEGF Treatment
Retinal layers changes in patients with age-related macular degeneration treated with intravitreal anti-VEGF agents
Fibrosis in age-related neovascular macular degeneration in the anti-VEGF era
Refractory neovascular age-related macular degeneration: time-dependent changes of central retinal thickness with anti-VEGF treatment
The effect of vitreomacular interface in neovascular age-related macular degeneration treated with intravitreal injection of anti-VEGF
Risk factors for breakthrough vitreous hemorrhage after intravitreal anti-VEGF injection in age-related macular degeneration with submacular hemorrhage
Anti-VEGF for the management of diabetic macular edema
Pachychoroid Neovasculopathy Disguising as Age-Related Macular Degeneration Treated by Spironolactone and Anti-VEGF Combination Therapy
Hyperreflective material evolution patterns during long term anti-VEGF therapy in neovascular age-related macular degeneration
A Systematic Review of the Treat and Extend Treatment Regimen with Anti-VEGF Agents for Neovascular Age-Related Macular Degeneration
Atrophy of retinal vessels in neovascular age-related macular degeneration following long-term treatment with 20 intravitreal anti-VEGF injections